Setbacks tarnish Bristol-Myers' 'string of pearls'

Bristol-Myers Squibb's ($BMY) "string of pearls" is starting to look a little dull to investors. After watching its expensive hepatitis C drug from Inhibitex go up in flames while regulators slowed the progress of its blood-thinner Eliquis, its shares have slid this year after seeing a big gain in 2011. And some top analysts don't see a quick turnaround in the offing. "Right now, I just don't see the catalyst in 2012, or even in early 2013, to own Bristol," ISI Group's Mark Schoenebaum told Bloomberg. "The price- earnings ratio is at such a premium to the rest of the group." Story

 

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.